First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is...

被引：3
|
作者：
Juan, O. [1 ,2 ]
Yousaf, N. [2 ]
Popat, S. [2 ,3 ,4 ]
机构：
[1] Univ Hosp La Fe, Dept Med Oncol, Valencia, Spain
[2] Royal Marsden Hosp, Lung Unit, London, England
[3] Imperial Coll London, Fac Med, Natl Heart & Lung Inst, London, England
[4] Inst Canc Res, London, England
来源：
CLINICAL ONCOLOGY | 2017年 / 29卷 / 01期
关键词：
OPEN-LABEL; PHASE-III; PROGRESSION-FREE; CHEMOTHERAPY; ERLOTINIB; AFATINIB; ADENOCARCINOMA; MUTATIONS; GEFITINIB; SURVIVAL;
D O I：
10.1016/j.clon.2016.09.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E1 / E4
页数：4
相关论文
共 50 条
  • [1] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation
    Huang, Aimi
    Li, Rong
    Zhao, Jikai
    Wang, Xiaofei
    Jin, Bo
    Niu, Yanjie
    Zhang, Jie
    Jiang, Liyan
    Han, Baohui
    THORACIC CANCER, 2016, 7 (05) : 614 - 618
  • [2] Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
    Cascone, T
    Morelli, MP
    Ciardiello, F
    ANNALS OF ONCOLOGY, 2006, 17 : 46 - 48
  • [3] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
    Moriya, Tetsuji
    Hamaji, Masatsugu
    Yoshizawa, Akihiko
    Miyata, Ryo
    Noguchi, Misa
    Tamari, Shigeyuki
    Chiba, Naohisa
    Miyamoto, Hideaki
    Toyazaki, Toshiya
    Tanaka, Satona
    Yamada, Yoshito
    Yutaka, Yojiro
    Nakajima, Daisuke
    Ohsumi, Akihiro
    Menju, Toshi
    Date, Hiroshi
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (03) : 416 - 423
  • [4] Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors
    Lee, Ching-Yi
    Lee, Shih-Wei
    Hsu, Yi-Chiung
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [5] The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer
    Liam, Chong-Kin
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S448 - S452
  • [6] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [7] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
    Eric Nadler
    Melissa Pavilack
    Janet L. Espirito
    Jamyia Clark
    Ancilla Fernandes
    Advances in Therapy, 2020, 37 : 946 - 954
  • [8] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
    Nadler, Eric
    Pavilack, Melissa
    Espirito, Janet L.
    Clark, Jamyia
    Fernandes, Ancilla
    ADVANCES IN THERAPY, 2020, 37 (02) : 946 - 954
  • [9] Efficacy of cranial radiotherapy prior to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer patients with brain metastases
    Tsushita, N.
    Goto, Y.
    Shiraishi, H.
    Tsuruoka, K.
    Yoshida, K.
    Itahashi, K.
    Asao, T.
    Kitahara, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Nokihara, H.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [10] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
    Masood, Ashiq
    Kancha, Rama Krishna
    Subramanian, Janakiraman
    SEMINARS IN ONCOLOGY, 2019, 46 (03) : 271 - 283
12345